

**EPIDEMIOLOGY OF HEPATITIS B AND C VIRUS INFECTIONS  
AMONGST HIV PATIENTS ON HIGHLY ACTIVE ANTI-RETROVIRAL  
THERAPY IN SOUTHEASTERN NIGERIA.**

**BY**

**OKOLI, CHUKWUDUM .S.  
NAU/PG/Ph.D/2013487011F**

**A DISSERTATION SUBMITTED TO THE  
DEPARTMENT OF APPLIED MICROBIOLOGY AND BREWING,  
FACULTY OF BIOSCIENCES,  
IN PARTIAL FULFILLMENT OF THE REQUIREMENT  
FOR THE AWARD OF THE DEGREE OF DOCTOR OF PHILOSOPHY  
(Ph.D) IN MICROBIOLOGY (MEDICAL MICROBIOLOGY) OF NNAMDI  
AZIKIWE UNIVERSITY, AWKA.**

**SUPERVISOR: PROF R.A.U. NWOBU**

**SEPTEMBER, 2019.**

## **CERTIFICATION**

This is to certify that this research work titled “EPIDEMIOLOGY OF HEPATITIS B AND C VIRUS INFECTIONS AMONGST HIV PATIENTS ON HIGHLY ACTIVE ANTI-RETROVIRAL THERAPY IN SOUTHEASTERN NIGERIA” was carried out by Okoli, Chukwudum S, with Registration number NAU/PG/Ph.D/2013487011F, under the supervision of Prof. R.A.U. Nwobu, this work is original and has not been submitted in part or full for any other university.

.....  
C. S. Okoli

.....  
Date

## APPROVAL

This dissertation titled “EPIDEMIOLOGY OF HEPATITIS B AND C VIRUS INFECTIONS AMONGST HIV PATIENTS ON HIGHLY ACTIVE ANTI-RETROVIRAL THERAPY IN SOUTHEASTERN NIGERIA” by Okoli Chukwudum Somadina with registration number NAU/PG/Ph.D/2013487011F has been approved for the award of Doctor of Philosophy (Ph.D) in Medical Microbiology, in the Department of Applied Microbiology and Brewing, Faculty of Biosciences, Nnamdi Azikiwe University Awka.

.....  
Prof R.A.U. Nwobu  
(Supervisor)

.....  
Date

.....  
Dr. C. C. Ekwealor  
(H.O.D, Applied Microbiology and Brewing)

.....  
Date

.....  
Prof. C. A. Ekwunife  
(P.G Sub-Dean, Faculty of Biosciences)

.....  
Date

.....  
Prof. M. U. Orji  
(Dean, Faculty of Biosciences)

.....  
Date

.....  
External Examiner

.....  
Date

.....  
Prof. P. K. Igbokwe  
(Dean, School of Postgraduate Studies)

.....  
Date

## **DEDICATION**

This work is dedicated to my parents Surv. and Mrs. Afam Nwadinobi Okoli.

## ACKNOWLEDGEMENT

All Glory to the Most High for giving me the gifts of light, life and love throughout my academic pursuit and providing financial, moral support through my parents and siblings. My sincere appreciation goes to my supervisor, Prof. R. A. U. Nwobu, for his support throughout the supervision of this entire work, for his guidance, ever encouraging attitude and fatherly advice. May God continue to bless and reward him abundantly.

I have the honour to express my deep sense of gratitude and indebtedness to all the lecturers in the Department of Applied Microbiology and Brewing, Nnamdi Azikiwe University Awka who taught and assisted me in the facilitation of this programme. My profound gratitude goes to the staff and management of Safety Molecular and Pathology Laboratory (SMPL), Enugu for their assistance. I also wish to thank my course mates especially Dr. Chioma Uzokwe, Dr. Benard Nnabuike, Dr. Charity Ezeji, Dr. Nwako, Francis, Dr. Ndidi Okoli, Dr. Amaka Pauline, Dr. Cater Umeoduagu, Dr. Marcel, Dr. Emmanuel Ugbo, Chukwudi Anyim and Cynthia for their unimaginable support and Love. My special thanks and appreciation goes to the staff and management of Federal Medical Centre Umuahia, Federal Medical Centre Owerri, Federal Teaching Hospital Abakaliki, Enugu State University Teaching Hospital and Chukwuemeka Odumegwu Ojukwu University Teaching Hospital Awka where I collected my samples.

Finally, I wish to thank my godparents and his family Mr. and Mrs. John Oduenyi Okafor, my siblings Chibuzor, Golibe, Nene and Chinaemelum, my nieces Shante Nneoma and Zimuzo, my In-Law Virginus, my fiancée Onyinyechi (Omalicham), All set of AMB 2005, my friends and well wishers Dr. Obioma Ezennia and Ezennia family, Dr. Uche Ekuma, Ekene, Charles, Jeff Ik, Frank Malizu, Uche Okeke, Ifeanyi Okafor, Dr. Val Unegbu, Mr. and Mrs. Chris Kemakolam, Dr. Uche Ekuma, and Dr. Victor Agah, for their individual and collective supports.

## ABSTRACT

Hepatitis B virus (HBV) and Hepatitis C virus (HCV) co-infection is the leading cause of morbidity and mortality in HIV infected patients especially in developing countries. These have been shown to decrease the life expectancy in the HIV infected patients. Hence this study was designed to study the epidemiology of HBV, HCV and HBV/HCV co-infections in HIV patients attending Government Tertiary Hospitals in Southeast Nigeria. A cross-sectional study was conducted among 2,500 HIV patients on highly active antiretroviral therapy (HAART) attending Government Tertiary Hospitals in Ebonyi, Enugu, Abia, Imo and Anambra. The hospitals are Federal Teaching Hospital Abakaliki, Enugu State University Teaching Hospital, Federal Medical Centre Umuahia, Federal Medical Centre Owerri and Chukwuemeka Odumegwu Ojukwu University Teaching Hospital Awka respectively from February 2016 to November 2017. Socio-demographic and risk factors were collected using a structured questionnaire. Hepatitis B and C sero markers were detected using an Enzyme Linked Immunosorbent Assay (ELISA) while HBV and HCV genotypes were detected by Polymerase Chain Reaction (PCR). Reitman-Frankel colorimetric method was used in determining Alanine aminotransferase (ALT) and Aspartate Aminotransferase (AST) while Phenolphthalein monophosphate method was used in the determination of Alkaline Phosphatase (ALP). Haemocue Haemoglobin meter 301 was used to test for Haemoglobin and the cluster of differentiation T- lymphocytes class-4 (CD4<sup>+</sup>) levels were also determined using CD4 test count kit with Cyflow Counter. DNA and RNA were extracted using roche high pure viral nucleic acid kits and amplified by AB3130 Applied Biosystem Thermocycler. The results were analyzed using percentage frequency (%) and Statistical Package for Social Sciences (SPSS) software, version 20.0 and statistical significance was considered at  $P < 0.05$ . Out of the 2,500 HIV patients sampled, 256 (10.2%), 175 (7.0 %) and 25 (1.0%) were positive for HBV infection, HCV infection and HBV/HCV co-infection, respectively. Enugu State showed the highest seroprevalence rate to hepatitis B virus surface antigen (HBsAg) with 62 (12.4%) and the least by Ebonyi State with seroprevalence rate of 42 (8.4%). In this study, 175(7.0%) were positive for Anti-HCV, the highest seroprevalence rate was recorded in Anambra and Enugu States with (10.0%) each and Imo State recorded the least seroprevalence (4.0%). The distribution of hepatitis B virus surface antigen showed that the age range of 31-40 years had the highest prevalence of 70 (17.5%) and the least prevalence was >70 years 6 (2.4%). Also, distribution of hepatitis C virus by age, 31 -40 years showed the highest prevalence of 70 (17.5%) and 51 -60 years showed the least prevalence of 15 (3.7%), but <10 years recorded 0.0%. Out of 1400 (56%) males and 1100 (44.0%) females 11.8% and 8.2% were sero positive to hepatitis B virus surface antigen (HBsAg) respectively, while 85 (6.1%) males and 90 (8.2%) females were positive to hepatitis C virus antibody. Associated risk factors and sociodemographic parameters of HIV patients positive to HBV, HCV and HBV/HCV co-infections showed statistical significance ( $P < 0.05$ ), hence are significant risk factors. This study showed that  $P > 0.05$  is not statistically significant with regards to haematological and biochemical parameters except for CD4<sup>+</sup> in HBV/HIV patients ( $P = 0.000$ ), also CD4<sup>+</sup> and AST in HCV/HIV patients ( $P = 0.000$  and  $0.006$ ) and ALT in HBV/HCV/HIV patients ( $P = 0.026$ ) which showed statistical significance ( $P < 0.05$ ). DNA and RNA genotyping respectively showed hepatitis B with genotype E and genotype 2 for hepatitis C virus. Homology with consensus sequence of HBV genotype E were 99% and that of HCV genotype 2 were 96-98%. The findings show the importance of screening for hepatitis B and viruses in HIV infected individuals. HBV and HCV being a co-morbid infection and a threat were recorded in Eastern Nigeria; hence there is a need to give health education concerning transmission, risk factors and prevention of these viral infections. Government should create centers for the vaccination of populace.

## TABLE OF CONTENTS

|                       |      |
|-----------------------|------|
| Title                 | i    |
| Certification         | ii   |
| Approval              | iii  |
| Dedication            | iv   |
| Acknowledgement       | v    |
| Abstract              | vi   |
| Table of Contents     | vii  |
| List of Tables        | xi   |
| List of Figures       | xii  |
| List of Plates        | xiii |
| List of Abbreviations | xiv  |

### CHAPTER ONE: INTRODUCTION

|                                 |   |
|---------------------------------|---|
| 1.1 Background                  | 1 |
| 1.2 Statement of the Problem    | 5 |
| 1.3 Justification for the Study | 6 |
| 1.4 Aim of the Study            | 6 |
| 1.5 Objectives                  | 6 |

### CHAPTER TWO: LITERATURE REVIEW

|   |    |
|---|----|
| 2.1 Virology/Structure of Hepatitis B Virus           | 8  |
| 2.1.1 Genome of Hepatitis B Virus                     | 9  |
| 2.1.2 Life Cycle and Replication of Hepatitis B Virus | 9  |
| 2.1.3 Epidemiology of Hepatitis B Virus Infection     | 12 |
| 2.1.4 Mode of Transmission of Hepatitis B Virus       | 13 |
| 2.1.5 Serological Markers for Hepatitis B Virus       | 15 |

|  |    |
|--|----|
| 2.1.6 Pathogenesis of Hepatitis B Virus                      | 15 |
| 2.1.7 Natural History of HBV Infection                       | 16 |
| 2.1.8 Occult HBV Infection                                   | 20 |
| 2.1.9 HBV/HIV Co-Infection                                   | 22 |
| 2.1.10 Diagnosis of HBV                                      | 24 |
| 2.1.11 Prevention and Control of Hepatitis B Virus           | 27 |
| 2.2 Virology and Molecular Characteristics Hepatitis C Virus | 32 |
| 2.2.1 HCV Replication  | 34 |
| 2.2.2 Transmission of Hepatitis C Virus                      | 38 |
| 2.2.3 Clinical Features of Hepatitis C virus                 | 40 |
| 2.2.4 Epidemiology of Hepatitis C Virus                      | 42 |
| 2.2.5 Diagnosis of Hepatitis C Virus                         | 45 |
| 2.2.6 Prevention of Hepatitis C Virus                        | 46 |
| 2.2.7 Therapy and Prophylaxis of Hepatitis C Virus           | 46 |
| 2.3 Molecular Structure of HIV                               | 47 |
| 2.3.1 HIV Genome   | 49 |
| 2.3.2 Genetics of HIV  | 54 |
| 2.3.3 Pathogenesis of HIV                                    | 57 |
| 2.3.4 Clinical Signs Associated with HIV Infection           | 59 |
| 2.3.5 Laboratory Diagnosis of HIV                            | 60 |
| 2.3.6 Immunity to HIV Infection                              | 62 |
| 2.3.7 Epidemiology of HIV                                    | 63 |
| 2.3.8 Treatment of HIV Infection                             | 66 |
| 2.3.9 Prevention and Control of HIV Infection                | 69 |

## **CHAPTER THREE: MATERIALS AND METHODS**

|  |    |
|--|----|
| 3.1 Study Area   | 73 |
| 3.2 Study Population and Sample Size   | 73 |
| 3.3 Experimental Design  | 74 |
| 3.4 Ethical Approval   | 76 |
| 3.5 Inclusion and Exclusion Criteria   | 76 |
| 3.6 Questionnaire Administration   | 76 |
| 3.7 Collection of Blood Samples  | 77 |
| 3.8 Confirmation of HIV Status   | 77 |
| 3.9 Determination of Immunological Profile of Patients                                 | 78 |
| 3.10 Determination of Haematological Profile of Patients                               | 79 |
| 3.11 Alanine Aminotransferase Activity (ALT- Test)                                     | 79 |
| 3.12 Aspartate Aminotransferase Activity (AST-Test)                                    | 81 |
| 3.13 Alkaline Phosphatase Activity (ALP-Test)  | 82 |
| 3.14 Determination of Hepatitis B Seromarker (HBsAg)                                   | 83 |
| 3.15 Determination of Hepatitis B Seromarker (Anti-HBcIgM)                             | 85 |
| 3.16 Determination of Hepatitis B Seromarker (Anti-HBs)                                | 86 |
| 3.17 Determination of Hepatitis B Seromarker Anti-HBc Total                            | 86 |
| 3.18 Determination of Hepatitis C Seromarker (Anti-HCV)                                | 87 |
| 3.19 Determination of Hepatitis D Seromarker (HDV IgG)                                 | 89 |
| 3.20 Determination of Hepatitis D Seromarker (HDV Total Antigen)                       | 91 |
| 3.21 Extraction of Viral RNA or Viral DNA Using Roche High Pure Viral Nucleic Acid Kit | 91 |
| 3.22 Measurement of Hepatitis B Viral Load   | 93 |

|   |     |
|---|-----|
| 3.23 Detection of HBV S Region by Singleplex PCR  | 94  |
| 3.24 Determination of Hepatitis B Virus Genotypes Using Multiplex PCR                                     | 95  |
| 3.25 Determination of Hepatitis C Virus Genotypes   | 96  |
| 3.26 Measurement of Hepatitis C Viral Load Using 5x Quantitect<br>Virus Master Mix                        | 99  |
| 3.27 Detection of HBV-DNA by Nested PCR (PCR Amplification)   | 101 |
| 3.28 Determination of Genetic Relatedness of Hepatitis B Genotypes<br>(Homology with Consensus Sequence). | 102 |
| 3.29 Determination of Genetic Relatedness of Hepatitis C Genotypes<br>(Homology with Consensus Sequence). | 103 |
| 3.30 Statistical Analysis   | 104 |
| <b>CHAPTER FOUR: RESULTS</b>  | 105 |
| <b>CHAPTER FIVE: DISCUSSION</b>   | 146 |
| 5.1 Conclusion  | 166 |
| 5.2 Recommendations   | 167 |
| References  | 169 |
| Appendix  | 199 |

## LIST OF TABLES

| <b>Table</b> | <b>Title</b>   | <b>Page</b> |
|--------------|--|-------------|
| 2.1:         | Stages of chronic HBV Infection  | 19          |
| 2.2:         | Serological patterns in HBV Infection  | 21          |
| 3.1          | Reaction Components for RT, Primary and Secondary PCR Mixtures                     | 97          |
| 3.2          | Thermo cycling conditions used for RT, Primary and Secondary PCR Mixtures          | 98          |
| 3.3:         | Primers and Probe Mix Used at 10 $\mu$ M Concentrations                            | 100         |
| 4.1:         | Seroprevalence of HBV Markers amongst HIV Patients in SouthEast, Nigeria           | 106         |
| 4.2:         | Distribution of HBV Sero-Markers amongst HIV Patients by Age in SouthEast, Nigeria | 110         |
| 4.3:         | Risk Factors Distribution amongst HIV Patients with respect to HBV Sero-Status     | 124         |
| 4.4:         | Risk Factors Distribution amongst HIV Patients with respect to HCV Sero-Status     | 127         |
| 4.5:         | Socio–Demographic Characteristics of HBV Sero-Status in HIV Patients               | 130         |
| 4.6:         | Socio–Demographic Characteristics of HCV Sero-Status in HIV Patients               | 132         |
| 4.7:         | Hematological and Biochemical Parameters among HBV/HIV Patients                    | 134         |
| 4.8:         | Hematological and Biochemical Parameters among HCV/HIV Patients                    | 136         |
| 4.9:         | Hematological and Biochemical Parameters among HIV/HBV/HCV Patients                | 138         |
| 4.10         | Genotype and Homology with Consensus Sequence of Hepatitis B and C Viruses         | 145         |

## LIST OF FIGURES

| <b>Figure</b> | <b>Title</b>  | <b>Page</b> |
|---------------|---|-------------|
| 2.1:          | Replication of HBV  | 11          |
| 2.2:          | HCV Replication   | 35          |
| 4.1:          | Seroprevalence of HCV Markers amongst HIV Patients in SouthEast, Nigeria                  | 107         |
| 4.2:          | Seroprevalence of HBV/HCV Co-infection amongst HIV Patients in SouthEast, Nigeria         | 109         |
| 4.3:          | Distribution of HCV Sero-Markers amongst HIV Patients by Age in Southeast, Nigeria        | 113         |
| 4.4:          | Distribution of HBV Sero-markers amongst HIV Patients by Sex in SouthEast, Nigeria        | 114         |
| 4.5:          | Distribution of HCV Sero-markers amongst HIV patients by Sex in SouthEast, Nigeria        | 115         |
| 4.6:          | Seroprevalence of HBV Serological Markers in AHB Patients                                 | 116         |
| 4.7:          | Seroprevalence of HBV Serological Markers in CHB HIV Patients                             | 117         |
| 4.8:          | Seroprevalence of HDV and HCV Markers among HBV Patients                                  | 118         |
| 4.9:          | Seroprevalence of anti-HBcT and HBV DNA among HBsAg Negative HIV Patients                 | 120         |
| 4.10:         | Profile of Hepatitis B Viral Load Results of Hepatitis B Surface Antigen (HBsAg) Positive | 121         |
| 4.11:         | Profile of hepatitis C viral load results of Hepatitis C positive patients                | 122         |

**LIST OF PLATES**

| <b>Plate</b> | <b>Title</b>                                  | <b>Page</b> |
|--------------|---|-------------|
| 3.1          | Map showing South East of Nigeria             | 75          |
| 4.1:         | PCR Amplification of Occult Hepatitis B Virus | 140         |
| 4.2:         | PCR Amplification of Hepatitis C Virus        | 141         |
| 4.3:         | Hepatitis B Virus Singleplex PCR              | 142         |
| 4.4:         | Hepatitis B Virus Genotyping by Multiplex PCR | 143         |

**LIST OF ABBREVIATIONS**

|          |                                       |
|----------|---------------------------------------|
| Ab       | Antibody                              |
| Ag       | Antigen                               |
| ALP      | Alkaline phosphatase                  |
| ALT      | Alanine Aminotransferase              |
| AST      | Aspartate Aminotransferase            |
| AIDS     | Acquired Immune Deficiency Syndrome   |
| Anti-HCV | Hepatitis C Virus Antibodies          |
| CAP/CTM  | CobasAmpliprep/CobasTaqman            |
| CDC      | Center for Disease Control            |
| ELISA    | Enzyme Linked Immunosorbent Assay     |
| cDNA     | Complimentary DNA                     |
| ddNTP    | Dideoxynucleotide triphosphate        |
| DNA      | Deoxyribonucleic acid                 |
| dNTP     | Deoxyribonucleotide triphosphate      |
| HAART    | Highly Active Anti-Retroviral Therapy |
| HCC      | Hepatocellular Carcinoma              |
| HBV      | Hepatitis B Virus                     |
| HCV      | Hepatitis C Virus                     |

|        |   |
|--------|---|
| Hb     | Haemoglobin                                     |
| HIV    | Human Immunodeficiency Virus                    |
| IU     | International Units                             |
| ORF    | Open Reading Frame                              |
| PCR    | Polymerase Chain Reaction                       |
| RFLP   | Restriction Fragment Length Polymorphism        |
| RNA    | Ribonucleic acid                                |
| RT-PCR | Reverse Transcriptase Polymerase Chain Reaction |
| UTR    | Untranslated Region                             |
| UV     | Ultra Violet Light                              |
| WHO    | World Health Organisation                       |